Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s Menelas Pangalos: An Interview With “The Pink Sheet” DAILY

This article was originally published in The Pink Sheet Daily

Executive Summary

With AstraZeneca in the midst of a major R&D overhaul, Menelas Pangalos, the company’s head of discovery research and early-stage development in small molecules, talked to “The Pink Sheet” DAILY about how the new R&D structure will improve the big pharma’s research productivity.

You may also be interested in...



AstraZeneca: New HQ And R&D Site Underscore Its U.K. Commitment

Design plans for AstraZeneca’s new, purpose-built global headquarters and R&D center being constructed in the university town Cambridge underscore the pure pharma’s commitment to innovative science as a standalone, U.K.-based company, says head of early development Menelas Panaglos.

No Surprise AstraZeneca Singles Out Emerging Markets For Growth, But Japan Too?

Japan offers AstraZeneca a patent expiry cushion as the company tries to right itself elsewhere.

AstraZeneca’s R&D Restructuring Follows Hot Spot Trend

In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel